CRISPR for Type 1 & 2 Diabetes Identification and Treatment | IDT
New CRISPR/Cas9 Technique to Potentially Cure Type 1 Diabetes Mellitus - European Medical Journal
CRISPR-based genome editing in primary human pancreatic islet cells | Nature Communications
A lentiviral CRISPR/Cas9 pipeline to genome edit EndoC-βH1. (A)... | Download Scientific Diagram
The Most Innovative Ways to Use CRISPR | OpenMind
Type-2 Diabetes and Gene Therapy: The Promise of CRISPR Gene Therapy in type-2 Diabetes Mellitus - Open Access Pub
CRISPR/Cas9 system - a revolution in gene editing
CRISPR Therapeutics and ViaCyte Tackling Type 1 Diabetes - YouTube
B.C. researchers launching clinical trial for first genetically engineered stem cell-based therapy for type 1 diabetes
Frontiers | Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement
Target gene activation via CRISPR/Cas9 used to treat type 1 diabetes, muscular dystrophy, and acute kidney disease in mouse models : r/science
CRISPR-Cas9 successfully reverses obesity in mice
Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells - ScienceDirect
Can CRISPR Therapeutics (CRSP) and ViaCyte CURE Type 1 Diabetes? | VCTX210 - YouTube
CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination - eBioMedicine
Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
CRISPR Therapeutics And ViaCyte Collaborate To Create Universal Stem Cell Therapies For Diabetes - Biobanking.com
Salk scientists modify CRISPR to epigenetically treat diabetes, kidney disease, muscular dystrophy - Salk Institute for Biological Studies
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis | NEJM
Frontiers | Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research
Strategies for durable β cell replacement in type 1 diabetes | Science
Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes | Nature Metabolism
ViaCyte | Regenerative Medicine Therapies for Diabetes
Frontiers | Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research
